Split hyperfractionated accelerated radiation therapy and concomitant @entity900 for locally advanced XXXX : a preliminary report.

@entity1 @entity135 @entity137 @entity5 @entity900 @entity25364
PURPOSE: The feasibility and activity of an intensive chemoradiotherapeutic scheme for @entity1 with locally advanced @entity135 were tested in a single institution Phase II pilot study. METHODS AND MATERIALS: Between January 1990 and February 1992, 40 @entity1 were entered into this trial. The treatment protocol consisted of split hyperfractionated accelerated radiation therapy (SHART), 1.6 Gy per fraction given twice per day to a total dose of 64-67.2 Gy for a total of 6 weeks with a 2-week gap, and @entity900 (20 mg/sqm/Days 1 to 5, in continuous perfusion) concomitantly. RESULTS: All of the 40 @entity1 are evaluable for response and survival. @entity137 was significant, but tolerable. A complete @entity5 response to this treatment was achieved by 37 @entity1 (92.5%). With a minimal follow-up of 22 months (median 30 months) there have been 16 local relapses and 19 @entity1 have died, 2 without @entity5 . The projected 2- and 3-year overall survival rates are 64% (confidence interval (CI) 95%, 49-79%) and 47%, respectively. The 2-year local control probability has been 56% (CI 95%, 39-73%). CONCLUSION: This treatment obtains a high rate of complete responses with increased acute @entity137 but tolerable late effects. Preliminary results are encouraging for @entity25364 . A longer follow-up is needed to evaluate the impact of this treatment on @entity1 survival.
